Clinical Trial Update: Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer [Phase 2]

View source ↗

Summary

A phase 2 neoadjuvant trial of anastrozole plus pazopanib in stage II/III estrogen receptor-positive, HER2-negative breast cancer was terminated, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Votrient (Pazopanib)

Snippet

Sponsor: University of Arizona | Conditions: Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Status: TERMINATED | Results posted: 2018-07-26